AstraZeneca's Novel ADC AZD5335 Shows Promising Early Clinical Data in Platinum-Resistant Ovarian Cancer

Oct 19, 2025 17:59 CST Updated 17:59

AstraZeneca

Biopharmaceutical Manufacturer

Abstract:At the 2025 ESMO Congress in Berlin, AstraZeneca PLC unveiled early clinical data for its internally developed novel antibody-drug conjugate (ADC), AZD5335. Targeting folate receptor α-positive platinum-resistant ovarian cancer, the drug demonstrated remarkable efficacy and manageable safety, affirming the company's strategic focus on advancing its internal ADC pipeline and positioning it to gain an edge in the highly competitive next-generation ADC market.

In-House Pipeline Finally Breaks Through with Excellent Early Data Performance

AstraZeneca previously solidified its position with two major ADC drugs, Enhertu and Datroway, the latter approved earlier this year in collaboration with Daiichi Sankyo. Now, the company’s shift to a self-developed strategy is reaching a critical validation point. Data from the Phase I/IIa clinical trial presented at the ESMO conference showed that AZD5335 demonstrated therapeutic effects within the dose range of 1.6-2.4mg/kg among 189 patients with platinum-resistant ovarian cancer.

At a median follow-up of 7.8 months, 56.2% of patients in this dose range showed no disease progression. The objective response rates across different dose groups were equally impressive, with the 1.6mg/kg group reaching 56%, the 2mg/kg group at 56.1%, and the 2.4mg/kg group at 49.2%. Matt Hellmann, Vice President of Early Oncology Development at AstraZeneca, highly praised this data, stating that it fully validates the reliability of the company's proprietary ADC platform.

Technical Advantages Build Barriers, Safety Recognized

The core competitiveness of this new drug stems from AstraZeneca's self-developed linker and topoisomerase I payload technology. Hermann emphasized that a stable linker-payload system is the core of future ADC portfolios. The company has drawn on experience from past collaboration projects and made long-term investments to build a proprietary ADC pipeline, with the goal of replacing traditional chemotherapy with ADC drugs.

In terms of safety, the drug demonstrated good tolerability. The most common treatment-related adverse reaction was neutropenia, with grade 3 or higher cases accounting for 45.9% in the 2.4mg/kg dose group. Notably, no significant toxicity was observed in the 1.6mg/kg and 2mg/kg dose groups, and all adverse reactions were payload-related, with no unexpected off-target toxicity, consistent with expectations.

Facing Market Competition Head-On, Independent Layout Demonstrates Confidence

The competition in the ADC field is currently at a fever pitch, with many companies entering the track through mergers and acquisitions or licensing collaborations. However, Herman expressed confidence in the company's market position, stating that AstraZeneca is one of the few enterprises to independently build an ADC technology platform and a library of surface markers, enabling flexible matching of targets with payloads and continuously driving innovation.

The release of clinical data for AZD5335 marks a crucial step forward for AstraZeneca in its self-developed ADC journey. As seven internally developed ADC drugs, covering both solid tumors and hematological malignancies, gradually progress, this pharmaceutical giant is using technology as its spear to carve out its own territory in the battle for next-generation cancer therapies.

Reference Source:https://www.fiercebiotech.com/biotech/esmo-astrazeneca-believes-latest-data-validate-betting-house-adc-pipeline

Scan the WeChat QR code, add the editor of the Biologics Circle, and those who meet the requirements can join.
Biological Products WeChat Group!
Please indicate: Name + Research Direction!

Edition
Authority
Sound
Ming
All reproduced articles in this official account are intended to convey more information, with the source and author clearly indicated. Media or individuals who do not wish to be reproduced can contact us at cbplib@163.com, and we will delete the content immediately. All articles represent the views of the author, not this site.